{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T13:41:15Z","timestamp":1785159675461,"version":"3.55.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004625","name":"Universiti Teknologi MARA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.thromres.2020.04.001","type":"journal-article","created":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T02:36:55Z","timestamp":1588732615000},"page":"12-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Anticoagulation control in different ethnic groups receiving vitamin K antagonist therapy for stroke prevention in atrial fibrillation"],"prefix":"10.1016","volume":"192","author":[{"given":"Hanis","family":"Zulkifly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Cheli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Lutchman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7883-0368","authenticated-orcid":false,"given":"Ying","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5604-9378","authenticated-orcid":false,"given":"Deirdre A.","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.thromres.2020.04.001_bb0005","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1160\/TH13-06-0443","article-title":"Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position Paper of the ESC Working Group on Thrombosis \u2013 Task Force on Anticoagulants in Heart Disease","volume":"110","author":"De Caterina","year":"2013","journal-title":"Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2020.04.001_bb0010","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11239-007-0106-9","article-title":"Determinants and measures of quality in oral anticoagulation therapy","volume":"25","author":"Kaatz","year":"2007","journal-title":"J. Thromb. Thrombolysis"},{"issue":"3","key":"10.1016\/j.thromres.2020.04.001_bb0015","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0038-1651587","article-title":"A method to determine the optimal intensity of oral anticoagulant therapy","volume":"69","author":"Rosendaal","year":"1993","journal-title":"Thromb. Haemost."},{"issue":"38","key":"10.1016\/j.thromres.2020.04.001_bb0020","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur. Heart J."},{"issue":"10046","key":"10.1016\/j.thromres.2020.04.001_bb0025","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S0140-6736(16)31257-0","article-title":"Stroke prevention in atrial fibrillation","volume":"388","author":"Freedman","year":"2016","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.thromres.2020.04.001_bb0030","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1161\/CIRCULATIONAHA.112.142158","article-title":"Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation","volume":"127","author":"Wallentin","year":"2013","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.thromres.2020.04.001_bb0035","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1378\/chest.13-0054","article-title":"Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the same-tt2r2 score","volume":"144","author":"Apostolakis","year":"2013","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.thromres.2020.04.001_bb0040","first-page":"1339","article-title":"Evaluation of quality of warfarin therapy by assessing patient's time in therapeutic range at a tertiary care hospital in Pakistan","volume":"68","author":"Hakeem","year":"2018","journal-title":"J. Pak. Med. Assoc."},{"issue":"10","key":"10.1016\/j.thromres.2020.04.001_bb0045","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/FPC.0000000000000298","article-title":"Quality of anticoagulation control and hemorrhage risk among African American and European American warfarin users","volume":"27","author":"Limdi","year":"2017","journal-title":"Pharmacogenet. Genomics"},{"issue":"1","key":"10.1016\/j.thromres.2020.04.001_bb0050","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1353\/hpu.2008.0002","article-title":"Quality of anticoagulation control: do race and language matter?","volume":"19","author":"Bhandari","year":"2008","journal-title":"J. Health Care Poor Underserved"},{"key":"10.1016\/j.thromres.2020.04.001_bb0055","series-title":"2011 Census: Key Statistics for Birmingham and It's Constituent Areas. Planning and Growth Strategy","year":"2012"},{"issue":"2","key":"10.1016\/j.thromres.2020.04.001_bb0060","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.thromres.2020.04.001_bb0065","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.thromres.2020.04.001_bb0070","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/europace\/euv088","article-title":"The SAMe-TT2R2 score and quality of anticoagulation in atrial fibrillation: a simple aid to decision-making on who is suitable (or not) for vitamin K antagonists","volume":"17","author":"Fauchier","year":"2015","journal-title":"Europace"},{"issue":"4","key":"10.1016\/j.thromres.2020.04.001_bb0075","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J. Thromb. Haemost."},{"issue":"35","key":"10.1016\/j.thromres.2020.04.001_bb0080","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1093\/eurheartj\/eht292","article-title":"The effects of apixaban on hospitalizations in patients with different types of atrial fibrillation: insights from the AVERROES trial","volume":"34","author":"Hohnloser","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.thromres.2020.04.001_bb0085","unstructured":"IBM SPSS Statistics for Windows, Version 23. Armonk, NY: IBM Corp."},{"issue":"1","key":"10.1016\/j.thromres.2020.04.001_bb0090","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.amjcard.2015.09.047","article-title":"Racial differences in quality of anticoagulation therapy for atrial fibrillation (from the TREAT-AF study)","volume":"117","author":"Yong","year":"2016","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.thromres.2020.04.001_bb0095","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ahj.2015.10.028","article-title":"Racial\/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry","volume":"174","author":"Golwala","year":"2016","journal-title":"Am. Heart J."},{"issue":"3","key":"10.1016\/j.thromres.2020.04.001_bb0100","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1177\/1062860614526282","article-title":"Explaining racial disparities in anticoagulation control","volume":"30","author":"Rao","year":"2014","journal-title":"Am. J. Med. Qual."},{"issue":"3","key":"10.1016\/j.thromres.2020.04.001_bb0105","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s40256-015-0120-9","article-title":"International normalized ratio stability in warfarin-experienced patients with nonvalvular atrial fibrillation","volume":"15","author":"Nelson","year":"2015","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"7","key":"10.1016\/j.thromres.2020.04.001_bb0110","first-page":"494","article-title":"Analysis of factors affecting time in therapeutic range control after warfarin administration","volume":"70","author":"Kose","year":"2015","journal-title":"Pharmazie"},{"issue":"1","key":"10.1016\/j.thromres.2020.04.001_bb0115","first-page":"70","article-title":"Predicting outcomes among patients with atrial fibrillation and heart failure receiving anticoagulation with warfarin","volume":"114","author":"Kim","year":"2015","journal-title":"Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.thromres.2020.04.001_bb0120","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.thromres.2013.09.003","article-title":"Patient factors against stable control of warfarin therapy for Japanese non-valvular atrial fibrillation patients","volume":"132","author":"Tomita","year":"2013","journal-title":"Thromb. Res."},{"issue":"3","key":"10.1016\/j.thromres.2020.04.001_bb0125","first-page":"232","article-title":"Quality of anticoagulation control among patients with atrial fibrillation","volume":"17","author":"Melamed","year":"2011","journal-title":"Am. J. Manag. Care"},{"issue":"10","key":"10.1016\/j.thromres.2020.04.001_bb0130","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1111\/j.1538-7836.2010.03996.x","article-title":"Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA)","volume":"8","author":"Rose","year":"2010","journal-title":"J. Thromb. Haemost."},{"issue":"8","key":"10.1016\/j.thromres.2020.04.001_bb0135","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/europace\/euv127","article-title":"Relationship between Mediterranean diet and time in therapeutic range in atrial fibrillation patients taking vitamin K antagonists","volume":"17","author":"Pignatelli","year":"2015","journal-title":"EP Europace"},{"issue":"2","key":"10.1016\/j.thromres.2020.04.001_bb0140","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.thromres.2015.06.007","article-title":"Determinants of oral anticoagulation control in new warfarin patients: analysis using data from Clinical Practice Research Datalink","volume":"136","author":"Macedo","year":"2015","journal-title":"Thromb. Res."},{"issue":"10","key":"10.1016\/j.thromres.2020.04.001_bb0145","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006814","article-title":"Prediction score for anticoagulation control quality among older adults","volume":"6","author":"Lin","year":"2017","journal-title":"J. Am. Heart Assoc."},{"issue":"3","key":"10.1016\/j.thromres.2020.04.001_bb0150","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1161\/CIRCOUTCOMES.113.000817","article-title":"Stratifying the risks of oral anticoagulation in patients with liver disease","volume":"7","author":"Efird","year":"2014","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"issue":"10","key":"10.1016\/j.thromres.2020.04.001_bb0155","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1111\/j.1538-7836.2008.03075.x","article-title":"Warfarin for atrial fibrillation in community-based practise","volume":"6","author":"Rose","year":"2008","journal-title":"J. Thromb. Haemost."},{"issue":"10","key":"10.1016\/j.thromres.2020.04.001_bb0160","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006669","article-title":"Clinical prediction model for time in therapeutic range while on warfarin in newly diagnosed atrial fibrillation","volume":"6","author":"Williams","year":"2017","journal-title":"J. Am. Heart Assoc."},{"issue":"Suppl. 2","key":"10.1016\/j.thromres.2020.04.001_bb0165","doi-asserted-by":"crossref","first-page":"e44S","DOI":"10.1378\/chest.11-2292","article-title":"Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Ageno","year":"2012","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.thromres.2020.04.001_bb0170","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJM199507063330103","article-title":"Optimal Oral anticoagulant therapy in patients with mechanical heart valves","volume":"333","author":"Cannegieter","year":"1995","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.thromres.2020.04.001_bb0175","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJM199507063330102","article-title":"Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia","volume":"333","author":"The European Atrial Fibrillation Trial Study Group","year":"1995","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.thromres.2020.04.001_bb0180","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.thromres.2020.04.001_bb0185","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.thromres.2020.04.001_bb0190","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.thromres.2020.04.001_bb0195","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.thromres.2020.04.001_bb0200","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/europace\/euu353","article-title":"Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists","volume":"17","author":"Abumuaileq","year":"2015","journal-title":"Europace"},{"issue":"4","key":"10.1016\/j.thromres.2020.04.001_bb0205","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s11739-014-1065-8","article-title":"A prospective validation of the SAME-TT2R 2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin","volume":"9","author":"Poli","year":"2014","journal-title":"Intern. Emerg. Med."},{"issue":"3","key":"10.1016\/j.thromres.2020.04.001_bb0210","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1378\/chest.13-2976","article-title":"RElationship of the same-tt2r2 score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation","volume":"146","author":"Lip","year":"2014","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.thromres.2020.04.001_bb0215","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.amjmed.2014.05.023","article-title":"SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation","volume":"127","author":"Gallego","year":"2014","journal-title":"Am. J. Med."},{"issue":"4","key":"10.1016\/j.thromres.2020.04.001_bb0220","first-page":"175","article-title":"Patients' understanding of anticoagulant therapy in a multiethnic population","volume":"96","author":"Nadar","year":"2003","journal-title":"J. R. Soc. Med."},{"issue":"1","key":"10.1016\/j.thromres.2020.04.001_bb0225","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1161\/hs0102.101817","article-title":"Ethnic differences in patient perceptions of atrial fibrillation and anticoagulation therapy the West Birmingham atrial fibrillation project","volume":"33","author":"Lip","year":"2002","journal-title":"Stroke"},{"issue":"9","key":"10.1016\/j.thromres.2020.04.001_bb0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074037","article-title":"Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial","volume":"8","author":"Clarkesmith","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.thromres.2020.04.001_bb0235","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2217\/pgs.14.88","article-title":"Genetic epidemiology of pharmacogenetic variations in CYP2C9, CYP4F2 and VKORC1 genes associated with warfarin dosage in the Indian population","volume":"15","author":"Giri","year":"2014","journal-title":"Pharmacogenomics"},{"issue":"3","key":"10.1016\/j.thromres.2020.04.001_bb0240","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.thromres.2014.05.028","article-title":"VKORC1 and CYP2C9 genotype distribution in Asian countries","volume":"134","author":"Gaikwad","year":"2014","journal-title":"Thromb. Res."},{"issue":"3","key":"10.1016\/j.thromres.2020.04.001_bb0245","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/clpt.2010.322","article-title":"The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans","volume":"89","author":"Perera","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.thromres.2020.04.001_bb0250","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/FPC.0b013e32831ebb30","article-title":"Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales","volume":"19","author":"Sistonen","year":"2009","journal-title":"Pharmacogenet. Genomics"},{"issue":"7","key":"10.1016\/j.thromres.2020.04.001_bb0255","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1517\/14622416.5.7.895","article-title":"Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population","volume":"5","author":"Solus","year":"2004","journal-title":"Pharmacogenomics"},{"issue":"3","key":"10.1016\/j.thromres.2020.04.001_bb0260","article-title":"Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data","volume":"12","author":"Lee","year":"2002","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.thromres.2020.04.001_bb0265","series-title":"Medical Genetics Summaries [Internet]","article-title":"Warfarin therapy and the genotypes CYP2C9 and VKORC1. 2012 Mar 8 [Updated 2016 Jun 8]","author":"Dean","year":"2012"},{"key":"10.1016\/j.thromres.2020.04.001_bb0270","doi-asserted-by":"crossref","unstructured":"Johnson J, Caudle K, Gong L, Whirl-Carrillo M, Stein C, Scott S, Michael Lee M, Gage B, Kimmel K, Perera M, Anderson J, Pirmohamed M, L.N. Klein T, Cavallari L, Wadelius M, Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.","DOI":"10.1002\/cpt.668"},{"issue":"3","key":"10.1016\/j.thromres.2020.04.001_bb0275","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1161\/01.STR.31.3.563","article-title":"Racial variation in initial stroke severity","volume":"31","author":"Jones","year":"2000","journal-title":"Stroke"},{"issue":"3","key":"10.1016\/j.thromres.2020.04.001_bb0280","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/oxfordjournals.aje.a009445","article-title":"Stroke incidence among white, black, and Hispanic residents of an urban Community The Northern Manhattan Stroke Study","volume":"147","author":"Sacco","year":"1998","journal-title":"Am. J. Epidemiol."},{"issue":"3","key":"10.1016\/j.thromres.2020.04.001_bb0285","first-page":"330","article-title":"Atrial fibrillation among African Americans, Hispanics and Caucasians: clinical features and outcomes from the AFFIRM trial","volume":"98","author":"Bush","year":"2006","journal-title":"J. Natl. Med. Assoc."},{"issue":"2","key":"10.1016\/j.thromres.2020.04.001_bb0290","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11239-006-9022-7","article-title":"Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM)","volume":"23","author":"Ansell","year":"2007","journal-title":"J. Thromb. Thrombolysis"},{"issue":"15","key":"10.1016\/j.thromres.2020.04.001_bb0295","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1001\/archinte.160.15.2343","article-title":"Oral anticoagulation management in primary care with the use of computerized decision support and near-patient testing: a randomized, controlled trial","volume":"160","author":"Fitzmaurice","year":"2000","journal-title":"Arch. Intern. Med."},{"issue":"3","key":"10.1016\/j.thromres.2020.04.001_bb0300","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1023\/B:THRO.0000011377.78585.63","article-title":"Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range","volume":"15","author":"Schmitt","year":"2003","journal-title":"J. Thromb. Thrombolysis"},{"issue":"10","key":"10.1016\/j.thromres.2020.04.001_bb0305","first-page":"906","article-title":"Racial\/ethnic differences in the prevalence of atrial fibrillation among older adults\u2014a cross-sectional study","volume":"102","author":"Yuh-Jer Shen","year":"2010","journal-title":"J. Natl. Med. Assoc."},{"issue":"3","key":"10.1016\/j.thromres.2020.04.001_bb0310","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/jamacardio.2016.0529","article-title":"Differences in clinical and functional outcomes of atrial fibrillation in women and men: two-year results from the orbit-af registry","volume":"1","author":"Piccini","year":"2016","journal-title":"JAMA Cardiol."},{"issue":"4","key":"10.1016\/j.thromres.2020.04.001_bb0315","first-page":"695","article-title":"Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists","volume":"114","author":"Ruiz-Ortiz","year":"2015","journal-title":"Thromb. Haemost."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384820301080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384820301080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:41:16Z","timestamp":1758735676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384820301080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":63,"alternative-id":["S0049384820301080"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2020.04.001","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticoagulation control in different ethnic groups receiving vitamin K antagonist therapy for stroke prevention in atrial fibrillation","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2020.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}